3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
37
Lymphoma, Follicular
22
Lymphoma, Mantle-Cell
18
Lymphoma, Large B-Cell, Diffuse
14
Lymphoma, B-Cell, Marginal Zone
11
Lymphoma, Non-Hodgkin
10
Lymphoma
6
Neoplasms
4
Lymphoma, B-Cell
4
Leukemia
3
Waldenstrom Macroglobulinemia
2
Neoplasm, Residual
2
Leukemia, Hairy Cell
2
Leukemia, B-Cell
2
Dendritic Cell Sarcoma, Interdigitating
2
Recurrence
1
Oncology Patients Receiving Chemotherapy
1
Neoplasm Metastasis
1
Lymphoproliferative Disorders
1
Indolent Non-Hodgkin's Lymphoma
1
Indolent Non-Hodgkin Lymphoma
1
Disease
1
Cytokine Release Syndrome
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
Oxaliplatin
67
Capecitabine
60
Fluorouracil
58
Bevacizumab
54
Gemcitabine
51
Paclitaxel
50
Leucovorin
50
Irinotecan
40
Docetaxel
39
Carboplatin
39
Cisplatin
38
pembrolizumab
37
Nivolumab
37
Cetuximab
35
Sunitinib
25
Trastuzumab
24
Radiosurgery
24
Radiotherapy
21
Doxorubicin
21
Cyclophosphamide
21
Panitumumab
20
Drug Therapy
19
Pemetrexed
18
Everolimus
18
Sorafenib
17
Interleukin-2
16
Fulvestrant
16
Albumin-Bound Paclitaxel
16
atezolizumab
15
Erlotinib Hydrochloride
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm Metastasis
×
obinutuzumab
×
Clear all
NCT04880863
2025-03-03
NT-NAP-102-1
NeoTX Therapeutics Ltd.
Phase 2
Completed
38 enrolled
13 charts